Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Verteporfin × Breast × Clear all
NCT02939274 2018-07-20

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

Rogers Sciences Inc.

Phase 2 Unknown
15 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡